Endovastec(SH:688016) Sou Hu Cai Jing·2025-12-10 12:21Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has shown mixed financial performance in the third quarter of 2025, with a notable increase in revenue but a decline in net profit [2] - As of December 10, 2025, Xinmai Medical's stock closed at 91.62 yuan, with a slight increase of 0.22% and a trading volume of 8110 lots, amounting to a total transaction value of 73.91 million yuan [1] - The company reported a main revenue of 1.015 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] Group 2 - In the third quarter of 2025, Xinmai Medical achieved a single-quarter revenue of 300 million yuan, which is a significant year-on-year increase of 64.68%, but the net profit attributable to shareholders fell by 23.63% to 114 million yuan [2] - The company has a debt ratio of 15.85% and reported an investment income of 11.6 million yuan, with financial expenses recorded at -7.86 million yuan and a gross profit margin of 70.4% [2] - Over the past 90 days, 9 institutions have provided ratings for the stock, with 7 buy ratings and 2 hold ratings, and the average target price set by institutions is 136.03 yuan [2]